Empowered Patient Podcast Karen Jagoda

Joan Butters, CEO and Co-Founder of Xsolis works with health systems and health plans to automate medical necessity decisions and improve efficiency. Using data and AI, Xsolis helps clinicians make more informed decisions and reduces manual administrative work, resulting in time and cost savings and improved patient care. Addressing the challenges and pushback faced when introducing AI into healthcare, Joan emphasizes the importance of understanding the limitations and complexities of generative AI and the need for subject matter expertise in developing prompts to properly address friction points between providers and payers in the healthcare environment.
Joan explains, "More important to this audience are the administrative aspects and the impact of that back and forth on the cost of healthcare. We were very fortunate that we found a niche in what we were trying to solve for. Again, that was the medical necessity decision whether a patient required hospital-based care. And then, with that laser focus, we did a lot of research from both sides and found that there was a way to automate through the use of data and AI to solve some of those problems."
"There are definitely two areas that we have a direct impact on. As I said, one is the cost of healthcare—so big efficiency. If you think about what clinicians do when they're making a determination of hospital-based care, prior to Xsolis, those clinicians would be reading through multiple data points and not data points that were connected, which became a very manual process. With automation and artificial intelligence, our system allows that very costly staff to be much more efficient in making those determinations. Coupled with that, instead of clinicians doing administrative tasks, the automation we provide through AI and our technology frees the clinician to be back at the bedside with the patient."
#Xsolis #Healthcare #HealthcareAdministration #Workflow #RemovingWorkflowFriction #AI #MedicalNecessityDecisions #Clinicians
xsolis.com
Listen to the podcast here

Joan Butters, CEO and Co-Founder of Xsolis works with health systems and health plans to automate medical necessity decisions and improve efficiency. Using data and AI, Xsolis helps clinicians make more informed decisions and reduces manual administrative work, resulting in time and cost savings and improved patient care. Addressing the challenges and pushback faced when introducing AI into healthcare, Joan emphasizes the importance of understanding the limitations and complexities of generative AI and the need for subject matter expertise in developing prompts to properly address friction points between providers and payers in the healthcare environment.
Joan explains, "More important to this audience are the administrative aspects and the impact of that back and forth on the cost of healthcare. We were very fortunate that we found a niche in what we were trying to solve for. Again, that was the medical necessity decision whether a patient required hospital-based care. And then, with that laser focus, we did a lot of research from both sides and found that there was a way to automate through the use of data and AI to solve some of those problems."
"There are definitely two areas that we have a direct impact on. As I said, one is the cost of healthcare—so big efficiency. If you think about what clinicians do when they're making a determination of hospital-based care, prior to Xsolis, those clinicians would be reading through multiple data points and not data points that were connected, which became a very manual process. With automation and artificial intelligence, our system allows that very costly staff to be much more efficient in making those determinations. Coupled with that, instead of clinicians doing administrative tasks, the automation we provide through AI and our technology frees the clinician to be back at the bedside with the patient."
#Xsolis #Healthcare #HealthcareAdministration #Workflow #RemovingWorkflowFriction #AI #MedicalNecessityDecisions #Clinicians
xsolis.com
Download the transcript here

Sanjeev Redkar, Co-Founder, Executive Director, and President of Apollomics, focuses on difficult-to-treat cancers, such as lung cancer, brain cancer, and leukemias, not served by immune checkpoint inhibitors. Their approach targets the thematic pathway in cancer cells responsible for their growth and proliferation. In their drug development, AI and data analysis drive precision-targeted therapies based on tumor molecular profiling. They are developing the drugs Vebreltinib and Uproleselan, which can be used as standalone treatments or in combination with other therapies to treat rare cancers.
Sanjeev explains, "There's a pathway that is very important for the growth of cancer cells. This is proliferation, motility, migration, and invasion of cancer cells, and that's the thematic pathway. This is an important receptor, which is upstream in cell signaling of these cancer cells. This is when these pathways work well, these cells grow as normal homeostasis, normal growth of cells. When this pathway is disrupted in cancer cells, they tend to grow far more than what normal cells would. That's the pathway that we are going after. These are mutations in this pathway, in the genome amplification, gene amplification, and fusions, which lead for these particular cancers to grow well. If you are able to inhibit that pathway, then you are able to impart benefit to the patient. And that's what one of our main drugs, Vebreltinib, is going after."
"As a whole, in lung cancer, even though the checkpoint inhibitors have moved the needle in terms of five-year survival rates, the needle has been moved from about 25% to about 30%, 32%, which is still much lower than say breast cancer, prostate cancer, where the five-year survival rates are close to 80%, 90%. So, how we can win the battle against lung cancer and brain cancer is really using precision-targeted therapies. These slivers of cancers that have a particular mutation, that have a particular dysregulation, and having treatments for that allow these patients a targeted approach for a longer benefit as opposed to one treatment for the entire lung cancer population. That is why we go after the so-called slivers, which put them into the rare cancers bucket."
#Apollomics #RareDiseases #Cancer #LungCancer #Leukemias #BrainCancer #RareCancers #NextGenSequencing #MolecularProfiling #CancerMolecularProfiling #TumorMolecularProfiling #AI
Apollomics.com
Listen to the podcast here

Sanjeev Redkar, Co-Founder, Executive Director, and President of Apollomics, focuses on difficult-to-treat cancers, such as lung cancer, brain cancer, and leukemias, not served by immune checkpoint inhibitors. Their approach targets the thematic pathway in cancer cells responsible for their growth and proliferation. In their drug development, AI and data analysis drive precision-targeted therapies based on tumor molecular profiling. They are developing the drugs Vebreltinib and Uproleselan, which can be used as standalone treatments or in combination with other therapies to treat rare cancers.
Sanjeev explains, "There's a pathway that is very important for the growth of cancer cells. This is proliferation, motility, migration, and invasion of cancer cells, and that's the thematic pathway. This is an important receptor, which is upstream in cell signaling of these cancer cells. This is when these pathways work well, these cells grow as normal homeostasis, normal growth of cells. When this pathway is disrupted in cancer cells, they tend to grow far more than what normal cells would. That's the pathway that we are going after. These are mutations in this pathway, in the genome amplification, gene amplification, and fusions, which lead for these particular cancers to grow well. If you are able to inhibit that pathway, then you are able to impart benefit to the patient. And that's what one of our main drugs, Vebreltinib, is going after."
"As a whole, in lung cancer, even though the checkpoint inhibitors have moved the needle in terms of five-year survival rates, the needle has been moved from about 25% to about 30%, 32%, which is still much lower than say breast cancer, prostate cancer, where the five-year survival rates are close to 80%, 90%. So, how we can win the battle against lung cancer and brain cancer is really using precision-targeted therapies. These slivers of cancers that have a particular mutation, that have a particular dysregulation, and having treatments for that allow these patients a targeted approach for a longer benefit as opposed to one treatment for the entire lung cancer population. That is why we go after the so-called slivers, which put them into the rare cancers bucket."
#Apollomics #RareDiseases #Cancer #LungCancer #Leukemias #BrainCancer #RareCancers #NextGenSequencing #MolecularProfiling #CancerMolecularProfiling #TumorMolecularProfiling #AI
Apollomics.com
Download the transcript here

Kristen Helton, CEO and Co-Founder of Herself Health, provides comprehensive primary care designed specifically for women over 65, considering the unique health challenges these women face. The emphasis is on the importance of addressing women's health beyond reproductive health and the need for tailored treatment and screening for conditions that affect women differently than men. Kristen notes the underrepresentation of women, especially older women, in clinical trials and the need for further investigation. They aim to reduce bias and improve the quality of care for older women by adopting a person-centric approach, listening to patients' concerns, and building trust.
Kristen explains, "Almost half of the burdens of disease that women experience stem from conditions that affect women differently than men. So, a lot of these diseases, cardiovascular, chronic illness, gastroenterology, and depression, affect men differently than they affect women. We're very focused on how we treat women and screen them for different diseases. We take a really comprehensive health history. Women have a lot of data that we need to understand as we're putting together the picture of their overall health."
"I mean, 65 is young old, in fact. It's just the beginning, and there are a lot of differences between 65 and 75 and 85 and 95. We're talking about decades. So I'm also remiss in grouping 65 and up even into a single category. But you hit on something super important there, and that is women are not satisfied with the answer that's just what happens as you get older. It comes back to, in essence, the quality of life. I think this is where we're seeing some real success in our approach, which is yes, we want to do all of the important preventative, physical, behavioral health care. But we also want to understand the patient's goals and what they're trying to get to and maintain."
#HerselfHealth #WomensHealth #Healthcare #ValueBasedCare #PrimaryCare
herself-health.com
Listen to the podcast here

Kristen Helton, CEO and Co-Founder of Herself Health, provides comprehensive primary care designed specifically for women over 65, considering the unique health challenges these women face. The emphasis is on the importance of addressing women's health beyond reproductive health and the need for tailored treatment and screening for conditions that affect women differently than men. Kristen notes the underrepresentation of women, especially older women, in clinical trials and the need for further investigation. They aim to reduce bias and improve the quality of care for older women by adopting a person-centric approach, listening to patients' concerns, and building trust.
Kristen explains, "Almost half of the burdens of disease that women experience stem from conditions that affect women differently than men. So, a lot of these diseases, cardiovascular, chronic illness, gastroenterology, and depression, affect men differently than they affect women. We're very focused on how we treat women and screen them for different diseases. We take a really comprehensive health history. Women have a lot of data that we need to understand as we're putting together the picture of their overall health."
"I mean, 65 is young old, in fact. It's just the beginning, and there are a lot of differences between 65 and 75 and 85 and 95. We're talking about decades. So I'm also remiss in grouping 65 and up even into a single category. But you hit on something super important there, and that is women are not satisfied with the answer that's just what happens as you get older. It comes back to, in essence, the quality of life. I think this is where we're seeing some real success in our approach, which is yes, we want to do all of the important preventative, physical, behavioral health care. But we also want to understand the patient's goals and what they're trying to get to and maintain."
#HerselfHealth #WomensHealth #Healthcare #ValueBasedCare #PrimaryCare
herself-health.com
Download the transcript here